AOTMiT: The Transparency Council will evaluate drugs, health programs and benefits

The agenda includes:

1 Prepare a position paper on the qualification of the M-Typer health care service for the diagnosis of mycobacteriosis and other mycobacterioses.

2 Prepare a position paper on the evaluation of the drug Vabinxo (valsartanum + indapamidum) for the indication: treatment of spontaneous hypertension, as substitution treatment in adult patients adequately controlled with valsartan and indapamide administered simultaneously at the same dose as in combination, but in the form of separate tablets.

3 Prepare a position paper to examine the appropriateness of issuing reimbursement approvals for the medicinal product Oxervate, (cenegerminum) for the indication: neurotrophic keratitis in adults.

4 Prepare a position paper to examine the appropriateness of issuing reimbursement approvals for the medicinal product Emcitate for the indication: Allan-Herndon-Dudley syndrome.

5 Prepare a position paper on the examination of the appropriateness of issuing reimbursement approvals for the medicinal product Lorenzo's Oil for the indication: adrenoleukodystrophy.

6 Prepare an opinion on the draft health policy program of the local government unit "Childbirth school - antenatal education program for parents-to-be in the Municipality of Debrzno for 2024-2026".

7 Prepare an opinion on the draft health policy program of the local government unit "Health policy program on prevention and early detection of prostate cancer risk by gene sequencing for residents of the Municipality of Torun for 2025-2029".

8 Prepare an opinion on the draft health policy program of the local government unit "Rehabilitation of oncology patients from the Świętokrzyskie region.

9. preparation of an opinion on the draft health policy program of the local government unit "Health policy program in support of diagnosis and treatment of infertility in the Lower Silesian Province".

10. Prepare an opinion on the reimbursement of the active substance cholecalciferolum in the indication: post-steroid osteoporosis - prevention.

11. Preparation of an opinion on the reimbursement of the active substance risedronatum natricum in the indication: post-steroid osteoporosis - prevention.

12 Prepare an opinion on the reimbursement of the active substance azathioprinum for the indication: autoimmune diseases other than those specified in the SmPC.

13 Prepare an opinion on the reimbursement of the active substance cyclophosphamidum in the indication: autoimmune diseases; amyloidosis.

14. Preparation of an opinion on reimbursement of the active substance acidum folicum in the indication: rheumatic diseases - in patients treated with methotrexate.

Source: AOTMiT